Join
Live feed
·
PRReleasevia Quantisnow
CRISPR Therapeutics AG logo

CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

ByQuantisnow·Wall Street's wire, on your screen.
CRSP· CRISPR Therapeutics AG
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRSP (CRISPR Therapeutics AG) and more on Quantisnow.